Skip to content

A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia

A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032205
Enrollment
Unknown
Registered
2020-04-23
Start date
2020-04-15
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan 1st Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the convalescence of COVID-19 diagnostic criteria; 2. Short breath, hyperhidrosis, dry cough, chest distress, palpitation and other clinical discomfort symptoms of lung and heart function decline, in which 3 symptoms appear at the same time, or the visual analogue score of single symptom (VAS) >=4 points; 3. Patients who were discharged for more than 2 weeks were cured; 4. Aged 18-70 years old; 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Because of other reasons, such as shortness of breath, hyperhidrosis, dry cough, chest distress, palpitation, etc; 2. Patients with difficulty in taking drugs orally due to basic diseases; 3. There are serious basic diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestion, blood disease, neuropsychiatric disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc; 4. Allergic constitution, allergic to drugs involved in the treatment plan; 5. Pregnant or lactating women; 6. Those who can't cooperate in mental state, suffer from mental disease, have no self-control and can't express clearly; 7. Those who are participating in other clinical trials; 8. According to the judgment of the researchers, there will be patients with complicated enrollment or poor compliance that affect the efficacy and safety evaluation.

Design outcomes

Primary

MeasureTime frame
VAS;

Countries

China

Contacts

Public ContactXia Ping

Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan 1st Hospital)

xiapingfm@126.com+86 027-85332028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026